Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820.

Article  PubMed  Google Scholar 

Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40. https://doi.org/10.1016/j.mayocp.2019.01.013.

Article  PubMed  CAS  Google Scholar 

Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824–32. https://doi.org/10.1001/jamaoncol.2021.4932.

Article  PubMed  Google Scholar 

Lovly CM. Expanding horizons for treatment of early-stage lung cancer. N Engl J Med. 2022;386(21):2050–1. https://doi.org/10.1056/NEJMe2203330.

Article  PubMed  Google Scholar 

Faroni L, Collie L, Gabrielli F, Baldotto C, Moraes F. Role of stereotactic radiation therapy in operable and inoperable early-stage non-small cell lung cancer. Curr Treat Options Oncol. 2022;23(9):1185–200. https://doi.org/10.1007/s11864-022-01002-x.

Article  PubMed  Google Scholar 

Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448–57. https://doi.org/10.1016/S1470-2045(21)00401-0.

Article  PubMed  PubMed Central  Google Scholar 

Timmerman RD, Paulus R, Pass HI, et al. stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018;4(9):1263–6. https://doi.org/10.1001/jamaoncol.2018.1251.

Article  PubMed  PubMed Central  Google Scholar 

van den Berg LL, Klinkenberg TJ, Groen HJM, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol. 2015;10(5):826–31. https://doi.org/10.1097/JTO.0000000000000483.

Article  PubMed  Google Scholar 

Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85. https://doi.org/10.1056/NEJMoa2202170.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301–11. https://doi.org/10.1200/JCO.21.01308.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586–97. https://doi.org/10.1200/JCO.21.01497.

Article  PubMed  CAS  Google Scholar 

Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9(5):467–75. https://doi.org/10.1016/S2213-2600(20)30391-X.

Article  PubMed  CAS  Google Scholar 

Schild SE, Wang X, Bestvina CM, et al. Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(5):e317–20. https://doi.org/10.1016/j.cllc.2022.04.004.

Article  PubMed  PubMed Central  CAS  Google Scholar 

van der Woude LL, Gorris MAJ, Wortel IMN, et al. Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. J Immunother Cancer. 2022;10(10):e005248. https://doi.org/10.1136/jitc-2022-005248.

Article  PubMed  PubMed Central  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.

Article  PubMed  PubMed Central  Google Scholar 

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6. https://doi.org/10.1046/j.1445-2197.2003.02748.x.

Article  PubMed  Google Scholar 

Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023;402(10405):871–81. https://doi.org/10.1016/S0140-6736(23)01384-3.

Article  PubMed  PubMed Central  Google Scholar 

Monjazeb AM, Daly ME, Luxardi G, et al. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial. Nat Commun. 2023;14(1):5332. https://doi.org/10.1038/s41467-023-40813-w.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu TC, Stube A, Felix C, et al. Safety and efficacy results from iSABR, a phase 1 study of stereotactic ABlative radiotherapy in combination with durvalumab for early-stage medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2023;117(1):118–22. https://doi.org/10.1016/j.ijrobp.2023.03.069.

Article  PubMed  Google Scholar 

Hallqvist A, Koyi H, Petris L, et al. 63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID). J Thorac Oncol. 2021;16(4):S729–30.

Article  Google Scholar 

Nyman J, Hallqvist A, Lund JÅ, et al. SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121(1):1–8. https://doi.org/10.1016/j.radonc.2016.08.015.

Article  PubMed  Google Scholar 

Chang JY, Liu H, Balter P, et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012;7:152. https://doi.org/10.1186/1748-717X-7-152.

Article  PubMed  PubMed Central  Google Scholar 

Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290–6. https://doi.org/10.1200/JCO.2008.21.5681.

Article  PubMed  Google Scholar 

Baker S, Jiang W, Mou B, et al. Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial. Int J Radiat Oncol Biol Phys. 2022;114(4):617–26. https://doi.org/10.1016/j.ijrobp.2022.05.033.

Article  PubMed  Google Scholar 

Blake-Cerda M, Lozano-Ruíz F, Maldonado-Magos F, et al. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Lung Cancer. 2021;152:119–26. https://doi.org/10.1016/j.lungcan.2020.12.029.

Article  PubMed  CAS  Google Scholar 

Daly ME. Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy. J Clin Oncol. 2022;40(6):539–45. https://doi.org/10.1200/JCO.21.01611.

Article  PubMed  CAS  Google Scholar 

Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6. https://doi.org/10.1001/jama.2010.261.

Article  PubMed  PubMed Central  CAS